Roivant Sciences Announces FDA Approval of LISRAYA (brepocitinib)

What Happened
On August 28, 2026, Roivant Sciences Ltd. (ROIV) posted and filed a presentation announcing that the U.S. Food and Drug Administration approved LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis. The presentation was posted on the company’s investor “Events & Presentations” page and is included as Exhibit 99.1 to the Current Report on Form 8-K.

Key Details

• FDA approval granted for LISRAYA (brepocitinib) to treat adults with dermatomyositis (announced August 28, 2026).
• Roivant filed the presentation as Exhibit 99.1 to its Form 8-K dated August 28, 2026.
• Wholesale acquisition cost (WAC) disclosed: $35,000 for a 30-count bottle of 30 mg tablets.
• The company noted that website content is not incorporated by reference into the Form 8-K.

Why It Matters
This filing documents a material regulatory milestone—FDA approval—which legally permits Roivant to commercialize LISRAYA in the U.S. and provides initial pricing (WAC) information for investors. Investors should watch Roivant’s upcoming disclosures and commercial updates for details on launch timing, uptake, and financial impact.